Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

被引：0
|
作者：
McGregor, Bradley Alexander
Wang, Xin Victoria
Hamnvik, Ole-Petter R.
Cheung, Yee Ming
Wei, Xiao X.
Ravi, Praful
Fichorova, Raina N.
Sweeney, Christopher
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.
    Szmulewitz, Russell Zelig
    Holzbeierlein, Jeffrey
    Azad, Arun
    Iguchi, Taro
    Villers, Arnauld
    Alcaraz, Antonio
    Alekseev, Boris
    Shore, Neal D.
    Rosbrook, Brad
    Zohren, Fabian
    Ma, Jie
    Haas, Gabriel P.
    Gomez-Veiga, Francisco
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] OUTCOMES BY PROSTATE-SPECIFIC ANTIGEN LEVEL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY AND IMPLICATIONS FOR CLINICAL PRACTICE
    Huebner, Tamara
    Williams, Monique
    Shore, Neal
    El-Chaar, Nader
    Russell, David
    Armstrong, Andrew
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [33] A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
    Ye, Ding-Wei
    Gu, Weijie
    Han, Weiqing
    Luo, Hong
    Zhou, Fangjian
    He, Dalin
    Ma, Lulin
    Guo, Hongqian
    Liang, Chaozhao
    Chong, Tie
    Jiang, Jun
    Chen, Zhiwen
    Wang, Yong
    Zou, Qing
    Tian, Ye
    Xiao, Jun
    Huang, Jian
    Yang, Xinfeng
    Li, Junliang
    Jin, Chunlei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Adverse outcomes (AOs) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with intensified androgen deprivation therapy (ADT plus ).
    Mir, Nabiel Ali
    Akmal, Waqaas
    Imam, Maaz
    Giurcanu, Mihai
    Szmulewitz, Russell Zelig
    Stadler, Walter Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 113 - 113
  • [35] Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation plus enzalutamide plus /- zoledronic acid: The BonEnza study
    Buffoni, M.
    Dalla Volta, A.
    Valcamonico, F.
    Apollo, D. D.
    Zivi, A.
    Procopio, G.
    Sepe, P.
    Del Conte, G.
    Di Meo, N.
    Foti, S.
    Zamboni, S.
    Messina, C.
    Lucchini, E.
    Rizzi, A.
    Ravanelli, M.
    Zamparini, M.
    Zacchi, F.
    Suardi, N.
    Farina, D.
    Berruti, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S980 - S980
  • [36] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS
    Tombal, B.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Gratzke, C.
    Grabbert, M.
    Vilaseca, A.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Kapur, S.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Joensuu, H.
    Smith, M. R.
    Hussain, M.
    EUROPEAN UROLOGY, 2023, 83
  • [37] Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
    Francini, Edoardo
    Yip, Steven
    Ahmed, Shubidito
    Li, Haocheng
    Ardolino, Luke
    Evan, Carolyn P.
    Kaymakcalan, Marina
    Shaw, Grace K.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Alimohamed, Nimira S.
    Joshua, Anthony M.
    Heng, Daniel Y. C.
    Sweeney, Christopher J.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 130 - 134
  • [38] SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Lobbedez, F. Joly
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Krakowski, I.
    Laguerre, B.
    Rolland, F.
    Theodore, C.
    Deplanque, G.
    Ferrero, J. M.
    Pouessel, D.
    Mourey, L.
    Beuzeboc, P.
    Zanetta, S.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 294 - 294
  • [39] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
    Gratzke, C. J.
    Ozguroglu, M.
    Peer, A.
    Sendur, M. A. N.
    Retz, M.
    Goh, J. C. H.
    Loidl, W. C.
    Jayram, G.
    Byun, S-S.
    Kwak, C.
    Kwiatkowski, M.
    Kopp, R. Manneh
    Limon, J. C. Vazquez
    Penagos, J. F. Escobar
    De Giorgi, U. F. F.
    Trindade, K. M. D.
    Niu, C.
    Liu, Y.
    Poehlein, C. H.
    Rodriguez, J. M. Piulats
    ANNALS OF ONCOLOGY, 2023, 34 : S957 - S958
  • [40] Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo
    Klier, Jorg
    Koenig, Frank
    Schoenfelder, Robert
    Eichenauer, Rolf
    Johannsen, Manfred
    Beuke, Maike
    Binder, Manfred
    Brenneis, Horst
    Burkert-Scholz, Marcus
    Fieseler, Claus
    Jaeger, Andreas
    Nitz, Christian
    Reese, Stephan
    Romagnolo, Allesandro
    Schroeder, Joerg
    Hempel, Elke
    Doehn, Christian
    AKTUELLE UROLOGIE, 2022, 53 (06) : 517 - 525
12345